Last reviewed · How we verify
IIV4 and PPV23
IIV4 and PPV23 are inactivated influenza and pneumococcal vaccines that stimulate the immune system to produce antibodies against influenza virus strains and Streptococcus pneumoniae serotypes.
IIV4 and PPV23 are inactivated influenza and pneumococcal vaccines that stimulate the immune system to produce antibodies against influenza virus strains and Streptococcus pneumoniae serotypes. Used for Prevention of seasonal influenza (IIV4), Prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes in PPV23.
At a glance
| Generic name | IIV4 and PPV23 |
|---|---|
| Sponsor | China National Biotec Group Company Limited |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
IIV4 (inactivated influenza vaccine, quadrivalent) contains inactivated influenza virus antigens from four strains, while PPV23 (pneumococcal polysaccharide vaccine) contains polysaccharide antigens from 23 pneumococcal serotypes. Both vaccines work by presenting these antigens to the immune system, triggering B and T cell responses that generate protective antibodies and cellular immunity against the respective pathogens.
Approved indications
- Prevention of seasonal influenza (IIV4)
- Prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes in PPV23
Common side effects
- Injection site pain, erythema, or swelling
- Fever
- Myalgia or fatigue
- Headache
Key clinical trials
- Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis Population (PHASE4)
- Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4 (PHASE4)
- Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4 (PHASE4)
- Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IIV4 and PPV23 CI brief — competitive landscape report
- IIV4 and PPV23 updates RSS · CI watch RSS
- China National Biotec Group Company Limited portfolio CI